Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19

Eur J Clin Microbiol Infect Dis. 2023 Jun;42(6):799-801. doi: 10.1007/s10096-023-04599-5. Epub 2023 Apr 21.

Hong Foo¹, Fiona Phan², Melissa Bagatella², Irene Petrovski³, Vana Nagendra⁴, Priya Acharya³, Miriam Levy^{2

5}, Emilia Prakoso^{2

6}

¹ Department of Microbiology and Infectious Diseases, NSW Health Pathology - Liverpool, Sydney, Australia. hong.foo@health.nsw.gov.au.
² Department of Gastroenterology, Liverpool Hospital, Sydney, Australia.
³ Department of Gastroenterology, Campbelltown Hospital, Sydney, Australia.
⁴ Department of Microbiology and Infectious Diseases, NSW Health Pathology - Liverpool, Sydney, Australia.
⁵ University of New South Wales, Sydney, Australia.
⁶ Central Clinical School, The Faculty of Medicine & Health, University of Sydney, Sydney, Australia.

No abstract available

Publication types